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Abstract
Alzheimer's disease, the most common cause of dementia, is a progressive
neurodegenerative disorder characterised by amyloid-beta deposits in
extracellular plaques, intracellular neurofibrillary tangles of aggregated tau,
synaptic dysfunction and neuronal death. There are no cures for AD and
current medications only alleviate some disease symptoms.
Transgenic rodent models to study Alzheimer’s mimic features of human
disease such as age-dependent accumulation of abnormal beta-amyloid and
tau, synaptic dysfunction, cognitive deficits and neurodegeneration. These
models have proven vital for improving our understanding of the molecular
mechanisms underlying AD and for identifying promising therapeutic
approaches. However, modelling neurodegenerative disease in animals
commonly involves aging animals until they develop harmful phenotypes, often
coupled with invasive procedures.  studies are also resource, labour,In vivo 
time and cost intensive.
We have developed a novel organotypic brain slice culture model to study
Alzheimer’ disease which brings the potential of substantially reducing the
number of rodents used in dementia research from an estimated 20,000 per
year. We obtain 36 brain slices from each mouse pup, considerably reducing
the numbers of animals required to investigate multiple stages of disease. This
tractable model also allows the opportunity to modulate multiple pathways in
tissues from a single animal. We believe that this model will most benefit
dementia researchers in the academic and drug discovery sectors.
We validated the slice culture model against aged mice, showing that the
molecular phenotype closely mimics that displayed  , albeit in anin vivo
accelerated timescale. We showed beneficial outcomes following treatment of
slices with agents previously shown to have therapeutic effects  and wein vivo, 
also identified new mechanisms of action of other compounds. Thus,
organotypic brain slice cultures from transgenic mouse models expressing
Alzheimer’s disease-related genes may provide a valid and sensitive
replacement for   studies that do not involve behavioural analysis.in vivo
Keywords
Organotypic brain slice culture, neurodegeneration, amyloid-β, tau, Alzheimer’s
disease, transgenic mice, reduction
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Introduction
Alzheimer’s disease (AD), the most common cause of demen-
tia, currently affects around 35 million people worldwide and 
carries huge societal and economical costs. AD is a multi- 
factorial disease with two major pathological hallmarks; 
extracellular plaques composed of β-amyloid (Aβ) and intra-
cellular neurofibrillary tangles containing aggregated post- 
translationally modified tau. The only available treatments for 
AD target the symptoms of disease, but not disease course. 
Intensive research efforts are ongoing to better understand the 
biological causes of disease so that effective disease-modifying 
therapies can be developed.
Perhaps the most accepted models for AD research are 
transgenic rodents that express wild-type or mutant human 
AD-associated genes and recapitulate key molecular pheno-
types of AD. Mice are generally one of the best accepted animal 
models in neuroscience research since there is significant 
homology between the human and mouse genome, mice have a 
relatively short life span, well-defined genetic backgrounds, are 
amenable to further genetic manipulations, enable assessment 
of changes in behaviour, cognition, brain biochemistry and 
physiology during disease progression, and a battery of well- 
characterised tasks are available to study behaviour and cognition1.
Our calculations, based on a PubMed search using the terms 
“Alzheimer’s + transgenic + mouse” and assuming an average 
of 30 mice for each of the 700 papers published, suggest that 
over 20,000 transgenic mice were used in AD research in 2017. 
Due to the age-related neurodegenerative nature of the disease, 
this research often involves aging several cohorts of mice to 
observe disease progression. Allowing mice expressing AD- 
related genes to reach the terminal stages can result in severe 
phenotypes, and some studies are coupled with invasive proce-
dures such as advanced live imaging or collection of interstitial 
or cerebrospinal fluids.
Alternatives to in vivo AD research in mammalian systems 
include rodent and human cell lines manipulated to express 
genes of interest, however these can be criticised for lacking key 
features of differentiated post-mitotic neurons and can be prone 
to artefacts resulting from protein over-expression. Dissociated 
neural cell cultures are commonly used as a readily tractable 
model in which pathways of interest can be manipulated, 
however even co-culture systems do not completely replicate 
the complex connections between different neural cell types and 
the brain vasculature, and they cannot model the synaptic and 
anatomical connectivity of mammalian brain. The latter is also 
true for neural cells derived from human induced pluripotent 
stem cells (iPSCs). Recent reports using iPSC-derived neurons 
also highlights the extensive time in culture required before even 
subtle disease relevant changes are observed in these human 
neural cells2.
Organotypic brain slice cultures are a well-established technique. 
Slice cultures maintain a three-dimensional organisation with 
the preservation of cytoarchitecture and cell populations, and are 
an accessible system lending their application to electrophysi-
ology, morphology and biochemical analyses3,4. The interface-
slice culture method established by Stoppini and colleagues in 
19915 is the most common method to culture brain sections 
ex vivo. This relatively simple method cultures brain tissue 
explants from neonatal mice/rats on a porous membrane insert 
that acts as an interface between the humidified incubator 
atmosphere and the culture medium that provides nutrition5. 
Cultures can be maintained for several weeks in culture after 
explant and continue to develop and mature once plated6,7. 
Importantly, slice cultures are prepared from neonatal mice 
precluding aging transgenic mice to a stage when they develop 
a detrimental phenotype. In addition, 36 slices containing the 
cortex and hippocampus can be prepared from one postnatal 
mouse brain allowing multiple variables to be tested or 
manipulated in tissue from the same mice, thereby consider-
ably reducing the number of mice required as well as minimising 
experimental variation.
Research highlights
Scientific benefits:
•    Neurodegeneration in AD is progressive and age-
dependent and therefore many experiments rely upon 
animals developing a moderate to severe phenotype prior to 
assessment of disease parameters 
•    Aging slices in a culture dish obviates this requirement, as 
well as providing an in vitro system in which all neural cell 
types are present, and functional and anatomical connectivity 
is retained
3Rs benefits:
•    Brain slice cultures can be used as an alternative to some  
in vivo experiments thereby reducing the numbers of animals 
required for such studies 
•    Disease phenotypes are accelerated in brain slice culture 
models so equivalent data can be obtained from neonatal 
mice in 1 month of in vitro experiments rather than 12 months 
of aging in vivo from fewer total mice 
•    36 brain slices can be cultured from a single mouse brain, 
so studies can be refined as it is possible to assess several 
parameters or disease-modifying agents in a single brain 
thereby minimising biological variation
Practical benefits:
•    This model is considerably more time and cost effective when 
compared to in vivo studies
Current applications:
•    The 3xTg-AD slice culture model is suitable for biochemical 
and immunohistochemical research into Alzheimer’s disease 
and related tauopathies
Potential applications:
•    Long-term organotypic brain slice cultures have the potential 
for use in all aspects of neuroscience 
•    Cultures from other tissues will have utility for many other 
fields of biological and biomedical research
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AD researchers are beginning to embrace organotypic brain 
slice culture models, with recent papers describing AD-relevant 
changes in slice cultures prepared from mice that overexpress 
amyloid precursor protein or are seeded with Aβ, which show 
some accumulation of Aβ and synaptic alterations8–10. Others have 
shown that slice cultures prepared from mice that overexpress 
human tau can accumulate phosphorylated and some sarkosyl-
insoluble tau10,11. We recently demonstrated that slice cultures 
prepared from 3xTg-AD mice12 overproduce Aβ, accumulate 
somatodendritic and synaptic phosphorylated tau at an acceler-
ated rate compared to 3xTg-AD mice13, allowing study of Aβ-tau 
interactions and AD disease pathways ex vivo.
The utility of slice cultures for drug discovery efforts has 
previously been reviewed14, and we have validated 3xTg-AD 
slice cultures for this purpose by showing that the effects of 
disease-modifying compounds observed in vivo can be reca-
pitulated in slice culture15. We also identified novel targets for 
compounds, further demonstrating the usefulness of slice cultures 
for therapeutic development. In this paper, we provide detailed 
methods for the preparation of organotypic brain slice cultures 
for the study of AD and we discuss the advantages of this model 
system in terms of the 3Rs in AD research, most specifically in 
reducing mouse numbers. We believe that this model system 
will be of most benefit to researchers in the neurodegeneration 
field, who are either focussed on understanding the biological 
mechanisms underpinning disease or who aim to screen and test 
the efficacy of novel disease-modifying therapeutics.
Methods overview
Animals
3xTg-AD mice were obtained under a material transfer 
agreement from Professor Frank LaFerla (University of 
California Irvine, USA) and maintained as a breeding colony at 
King’s College London. 3xTg-AD mice express mutant human 
PS1 (M146V), APP (Swe, K670N, M671L) and tau (P301L) 
transgenes12. Wild-type (WT) mice of an identical background 
strain (F2 hybrid: C57BL/6J and 129S1/SvImJ) were main-
tained as background controls. All housing and experimental 
procedures were carried out in compliance with the local ethical 
review panel of King’s College London under a UK Home Office 
project licence held in accordance with the Animals (Scientific 
Procedures) Act 1986 and the European Directive 2010/63/
EU. Male and female mice were used in this study. After wean-
ing, mice were housed in single sex groups in standard 40 x 
25 x × 12 cm plastic cages. Bedding consisted of kiln dried 
aspen shavings and paper sizzle nest material (Datesand Ltd, 
Manchester, UK). Water and food were available (Picolab rodent 
diet 20; #5053; Lab Diet, St Louis, MO) ad libitum. Animals were 
housed at 19–22°C, humidity 55%, 12 h:12 h light: dark cycle 
with lights on at 07:30. Cages were cleaned once every two weeks, 
with mice handled by the tail by experienced animal care staff to 
transfer them between cages.
Slice culture preparation
Organotypic brain slice cultures were prepared from postna-
tal day 8-9 3xTg-AD16,17 and background control wild-type 
mice as previously described11. Briefly, pups were culled by 
decapitation in accordance with the UK Animals in Scientific 
Procedures Act (1986). Brains from pups were bisected into 
hemi-brains by a single cut along the midline. The cerebellum, 
thalamus and brainstem were removed and discarded to leave 
the cortex, hippocampus and connecting areas. These were kept 
in ice-cold dissection buffer (1.25 mM KH2PO4 pH 7.4, 124 mM 
NaCl, 3 mM KCl, 8.19 mM MgSO4, 2.65 mM CaCl2, 3.5 mM 
NaHCO3, 10 mM glucose, 2 mM ascorbic acid, 39.4 µM 
ATP in ultrapure H2O, sterile filtered (0.2 µm)) with constant 
oxygenation throughout the preparation procedure. 350 µm coro-
nal slices were cut using a McIlwain Tissue Chopper (Stoelting 
Europe, Ireland). Eighteen slices from each hemi-brain were 
collected and 3 consecutive slices per well were positioned on 
interface-style Millicell culture inserts (Millipore (UK) Ltd.) in 
6 well culture plates (ThermoFisher Scientific, UK) containing 
1 mL of sterile slice culture medium (Basal medium eagle 
(BME), 26.6 mM HEPES, pH 7.1, 19.3 mM NaCl, 5 mM 
NaHCO3, 511 µM ascorbic acid, 40 mM glucose, 2.7 mM 
CaCl2, 2.5 mM MgSO4, 1 % (v/v) GlutaMAX (Life Technolo-
gies, Paisley, UK), 0.033% (v/v) insulin, 0.5% (v/v) penicillin/ 
streptomycin (Life Technologies), in ultrapure H2O, sterile 
filtered (0.2 µm), plus 25% (v/v) heat inactivated horse serum 
(ThermoFisher, UK). Three hours after plating, the culture 
medium was removed by aspiration and replaced with 1 mL of 
pre-warmed fresh sterile culture medium. Brain slices were 
incubated at 37°C and the culture medium was changed from 
the bottom of each well every 2 to 3 days. Slices are maintained 
for a minimum of 14 days in vitro prior to treatment/harvesting.
Sample preparation and analysis
Slice cultures can be pharmacologically or genetically modified 
using a number of methodologies. These methods are out of the 
scope of this publication but have previously been published by 
ourselves and others (for example, 8–11,13,15).
Organotypic brain slice cultures can be fixed on their membrane 
inserts in 4% PFA for 4 h and stained according to Croft et al.13. 
In brief, slice cultures are cut whilst still on their membranes 
and then treated as free-floating sections. Slice cultures are 
permeabilised for 18h in 0.5% Triton X-100 at 4°C and then 
blocked in 20% bovine serum albumin (BSA) for 4h at RT. Slice 
cultures are incubated with primary antibodies overnight at 
4°C in 5% BSA, washed and then incubated with fluorophore- 
coupled secondary antibodies for 4h at ambient temperature. 
Slice cultures are washed a final time before mounting on slides 
with fluorescent mounting medium (Dako Ltd., Ely, UK) prior to 
imaging. 
Alternatively, tissue can be lysed for subcellular fractionation 
and/or biochemical analysis as described by us and others9–11,13,15. 
To prepare lysates for immunoblotting, slice culture medium 
is aspirated and slices washed once with ice-cold PBS. Slices 
are collected via scraping into ice-cold PBS. Cellular matter is 
pelleted by centrifugation at 7,000 g (av) for 30 seconds at 
ambient temperature. The supernatant is discarded and tissue 
pellets lysed in 100 µL ice-cold extra strong lysis buffer (10 mM 
Tris-HCl (pH 7.5), 0.5% (w/v) sodium dodecyl sulphate 
(SDS), 20 mM sodium deoxycholate, 1% (v/v) Triton-X-100, 
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75 mM sodium chloride, 10 mM ethylenediaminetetraacetic acid 
(EDTA), 2 mM sodium orthovanadate, 1.25 mM sodium fluo-
ride) and protease inhibitor cocktail for mammalian tissues 
(Roche Diagnostics, UK). The suspension is then sonicated briefly 
(10 seconds) using a Vibra-Cell™ probe sonicator to improve 
sample handling. Slice lysates are centrifuged at 23,000 g(av) 
for 20 minutes at 4°C and the supernatant collected. The pro-
tein content of the slice lysates can be determined using a BCA 
protein assay (Pierce Endogen, Rockford, USA) and protein 
concentration normalised prior to immunoblotting or ELISA. 
Slice lysates are mixed with an equal volume of 2x sample buffer 
before immunoblotting.
Culture medium can also be collected for analysis of its 
components, as we recently described for tau and Aβ13. Slice 
culture medium is replaced with Hank’s Balanced Salt Solution 
(HBSS; Life Technologies Ltd). HBSS is collected from the 
slice cultures and centrifuged at 12,000g for 10 min at 4°C to 
remove cell debris. Protein content in HBSS can be determined 
by ELISA by standard or sandwich ELISA.
Full protocol for the model development
Equipment required
McIllwain Tissue Chopper (RRID:SCR_015798; Mickle Labora-
tory Engineering Co. Ltd., Surrey, UK)
Stereomicroscope for tissue dissection
Chopping discs (Product code: 752TC-CT; Campden Instruments 
Ltd., Loughborough, UK)
Blades (Product code: TC752-1; Campden Instruments Ltd., 
Loughborough, UK)
55mm diameter ashless filter paper (Product code: WHA1442055; 
Merck, UK)
Flat (cover glass) forceps (Product code: 11074-02; Fine Science 
Tools, Heidelberg, Germany)
Cohan-Vannas Spring Scissors (Product code: 15000-02; Fine 
Science Tools, Heidelberg, Germany)
Mayo scissors (Product code: 14010-17; Fine Science Tools, 
Heidelberg, Germany)
Fine scissors, sharp (Product code: 14060-11; Fine Science Tools, 
Heidelberg, Germany)
Moria MC17C perforated spoon-mini (Product code: 10370-19; 
Fine Science Tools, Heidelberg, Germany)
Mini hippocampal dissection tool (Product code: 10099-12; Fine 
Science Tools, Heidelberg, Germany)
Cell culture treated 6-well plates (Product code: 140675; 
ThermoFisher Scientific, UK)
Cell culture treated 10cm dish (Product code: 172931; 
ThermoFisher Scientific, UK)
PTFE 30mm tissue culture inserts 0.4µm (Product code: 
PICM03050; Millipore, Fisher Scientific, UK)
Pasteur pipettes – sterile – individually wrapped (Product code: 
Z350621-400EA; Merck, UK)
30ml Pyrex beaker (Produce code: CLS100030; Merck, UK)
Fine paintbrush
Carbogen (95% Oxygen / 5% Carbon Dioxide)
Standard tissue culture incubator (37°C / 5% Carbon Dioxide)
Buffers and culture medium
Slice Culture Dissection buffer: 1.25 mM KH2PO4 pH 7.4, 124 mM 
NaCl, 3 mM KCl, 8.19 mM MgSO4, 2.65 mM CaCl2, 3.5 mM 
NaHCO3, 10 mM glucose, 2 mM ascorbic acid, 39.4 µM ATP in 
ultrapure H2O, sterile filtered (0.2 µm).
Slice culture medium: Basal medium eagle (BME), 26.6 mM 
HEPES, pH 7.1, 19.3 mM NaCl, 5 mM NaHCO3, 511 µM 
ascorbic acid, 40 mM glucose, 2.7 mM CaCl2, 2.5 mM MgSO4, 
1% (v/v) GlutaMAX (Life Technologies, Paisley, UK), 0.033% 
(v/v) insulin, 0.5% (v/v) penicillin/streptomycin (Life Tech-
nologies), in ultrapure H2O, sterile filtered (0.2 µm), plus 25% 
(v/v) heat inactivated horse serum (ThermoFisher, UK).
Methods
Brain extraction: 
Experiments are performed under sterile conditions with 
tools sterilised by autoclaving prior to use. 70% EtOH is used 
to sterilize equipment and surfaces throughout the experi-
ment. Postnatal day 8 or 9 WT or 3xTg-AD mice are used 
(Figure 1A–C).
1.    Pups are decapitated using Mayo scissors and death 
confirmed.
2.    Heads are transferred to a 10cm tissue culture dish 
containing oxygenated ice-cold dissection buffer.
3.    Fine scissors are used to remove hair and skin, cutting 
anteriorly from the base of the skull along the midline, revealing 
the brain and skull.
4.    Small spring scissors are used to carefully cut through the 
midline of the skull.
5.    The brain is bisected through the midline while remaining 
in the skull using a razor blade.
6.    The hippocampal dissection tool is used to cleanly remove 
the remove brainstem, cerebellum and thalamus which are 
discarded. The cortex, hippocampus and associated regions 
remain intact.
7.    The remaining tissue is removed from the skull and trans-
ferred to a glass beaker containing oxygenated dissection 
buffer.
8.    Repeat for the other hemi-brain. One hemi-brain will remain 
in dissection buffer, regularly re-oxygenated, while the other 
is processed.
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Figure 1. Preparation of organotypic brain slice cultures. (A) After removal from the skull, brains are bisected along the midline using a razor 
blade. (B) The thalamus, cerebellum and brain stem are removed using the hippocampal dissection tool leaving the cortex, hippocampus 
and connected brain regions. (C) Two hemi-brains are kept in oxygenated dissection buffer throughout the procedure; one hemi-brain is 
stored whilst the other is processed. (D) A hemi-brain is placed on dampened filter paper on the cutting surface of a McIlwain tissue chopper. 
(E–F) 350 µm coronal slices are cut. (G–J) Slice cultures are sequentially separated under a dissection microscope using a hippocampal 
dissection tool. (K) Three slices are plated per well on Millipore membrane inserts in 6 well plates. Three consecutive slices can be placed 
in each well or slices plated randomly depending on experimental needs. Cultures are maintained by replacing the culture medium every 
2–3 days.
Slice culture preparation (Figure 1D–K): 
9.    1 mL of slice culture medium is added to each well of a 
6-well culture plate. Flat cover glass forceps are used to add a 
Millicell culture insert into each well. The plate is returned to 
a 37°C incubator to ensure that culture medium is pre-warmed 
before slices are plated.
10.    A plastic chopping disc and fresh filter paper is placed on 
the cutting stage of a McIlwain tissue chopper. Three to four 
drops of dissection solution are used to dampen the filter 
paper and allow the hemi-brain to remain in place.
11.    A hemi brain is placed onto the filter paper and oriented for 
coronal sectioning (the front of the brain on the right-hand 
side).
12.    A drop of dissection solution is added to the brain to prevent 
the cutting blade from sticking.
13.    The section size on the McIllwain tissue chopper is adjusted 
to 350 µm. The blade should be manually positioned adjacent 
to the frontal region of the brain.
14.    The tissue chopper is started - the automated razor blade 
will cut 350 µm sections until manually switched off. The 
speed of cutting can be adjusted if necessary.
15.    The hemi-brain, remaining on the filter paper, is transferred 
to a fresh 10cm dish containing oxygenated dissection 
solution, and the dish is placed under a dissection 
microscope.
16.    Slices are manually separated using the hippocampal 
dissection tool, taking care to avoid ripping tissue. Using a 
plastic Pasteur pipette, individual slices are transferred to 
culture inserts in 6-well plate.
17.    From the leading edge (frontal cortex), three consecutive 
slices are positioned in each culture insert. Each hemi-brain 
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is sectioned into 18 slices, equivalent to one 6-well plate. 
Alternatively, slices can be plated randomly and distrib-
uted throughout wells allowing the study of frontal, middle 
and rostral sections within each well.
18.    Care should be taken to ensure that slices do not overlap or 
make contact with the sides of the insert. A fine paintbrush 
can be used to move the slices and to ensure that no areas 
of the slices are folded or wrinkled.
19.    Excess dissection solution is removed from the slice culture 
inserts, and the 6-well plate is returned to an incubator 
and maintained in humid conditions at 37°C with 5% CO2.
Slice culture maintenance: 
20.    In sterile conditions, approximately three hours after plating 
a glass Pasteur pipette is used to aspirate culture medium. 
1 mL pre-warmed fresh sterile culture medium is then added.
21.    Brain slices are incubated in humid conditions at 37°C with 
5% CO2. Culture medium is replaced every 2 to 3 days, 
taking care not to move the inserts within each well. Any 
excess medium which collects in the insert is also removed 
during media changes, taking care not to disturb the 
slices.
22.    Slice cultures can be analysed from 14 days after plating, 
at which time lactate dehydrogenase release should have 
returned to basal levels10.
NOTES: Practical considerations and tips
•     P8-P9 pups are used in this method, however other ages 
of pups are described in publications from other groups. 
It is likely that some optimisation may be required 
depending on the strain or transgenic line of mice being 
used.
•     Slice cultures are initially white in colour, but become 
translucent after 7 to 10 days in culture. White tissue 
remaining at this point is likely to signify unhealthy or dead 
tissue. 
•     It is important to cleanly remove all of the thalamus, 
cerebellum and brainstem during dissection since these are 
detrimental to slice survival under these conditions. These 
tissues can be cultured but using alternative protocols.
•     It is important that excess dissection buffer is removed 
from the slice cultures once they have been plated since 
prolonged exposure to this buffer in culture can affect slice 
health.
Results
Characterisation of the model: Organotypic brain slice 
cultures from 3xTg-AD mice recapitulate molecular features 
of AD and show an accelerated disease phenotype compared 
to in vivo
We have previously characterised organotypic brain slice cultures 
prepared from 3xTg-AD mice in comparison to brain from 
aged in vivo 3xTg-AD mice13. We examined abnormalities in 
β-amyloid and tau that accumulate in AD brain. We found that 
3xTg-AD slice cultures show an accelerated development of 
highly phosphorylated and oligomeric/64kDa tau species, some 
of which redistributed to synaptic compartments by 28 days 
in vitro (DIV). Similar changes in vivo are typically observed 
from 12 months of age. An accelerated accumulation of poten-
tially pathogenic Aβ species were also observed in brain slice 
cultures from 3xTg-AD mice, with significantly increased 
Aβ1-42 levels detected at 28 DIV in slices. In comparison, we 
could only detect significant changes in Aβ1-42 amounts in 
3xTg-AD brain in 12-month old mice. Thus, disease-associated 
protein species show an accelerated accumulation in long-term 
brain slice cultures in comparison to in vivo. Using differential 
centrifugation approaches we were also able to show the 
differential accumulation of phosphorylated and dephosphorylated 
tau species in synaptic compartments and at membranes, in 
agreement with previous reports using human tissue and pri-
mary cell cultures18,19. Table 1 provides a summary of molecular 
changes in the slice culture model in comparison to findings 
made using tissue from aged 3xTg-AD mice. Primary data is 
available here (Dataset 120).
There is also a great deal of versatility in the methods that can be 
used to assess disease changes in this model. We have confirmed 
that methods including, but not limited to the following, can be 
used with slice cultures; biochemical changes can be assessed 
by ELISA or immunoblotting, slice cultures can be examined by 
immunohistochemistry and confocal microscopy, sufficient 
material is present to allow differential centrifugation to enrich 
cell compartments such as synaptosomes, membrane and cytosol. 
Additionally, cell death can be measured using lactate dehy-
drogenase assays and the release of disease-associated proteins 
into culture medium can be quantified13,21. Others have also 
shown that brain slice cultures are amenable to ultrastructural 
analysis22, and live calcium imaging11.
Validation of the model: Organotypic brain slice cultures 
can be used to assess acute pharmacological treatments 
and to determine drug targets
In addition to comparing molecular features of AD in slice 
cultures in comparison to in vivo, we also validated the use of 
slice cultures for studying the effects on tau phosphorylation of 
acute application of compounds in comparison to their reported 
effects in previously published in vivo studies.
Lithium chloride (LiCl) can inhibit activity of the prominent tau 
kinase, glycogen synthase kinase-3β (GSK-3)23, which targets 
many of the tau residues known to be aberrantly phosphorylated 
in AD16. Treatment of 12-month-old 3xTg-AD mice for 
3 months with the GSK-3 inhibitor, LiCl, was shown to reduce 
phosphorylation of tau at Thr 181, Ser 202/Thr 205, Thr 231, 
and Thr 212/Ser 214, but not Ser 396/40424. We found that 
application of LiCl for 4 h to 3xTg-AD brain slice cultures at 
28 days days in vitro (DIV) resulted in significantly reduced tau 
phosphorylation at the Ser396/404 and Ser202/Thr205 epitopes, 
in addition to causing a subtle reduction in total tau amounts 
when compared to slices treated with control (NaCl). There was 
also a notable shift in the apparent molecular weight of tau in 
lysates from LiCl treated slice cultures, which is characteristic of 
reduced tau phosphorylation15.
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Table 1. Biochemical and pathological features of 3xTg-AD organotypic brain slices in comparison to in vivo 3xTg-AD brain 
and AD brain. Primary references are shown. AD: Alzheimer’s disease; DIV: days in vitro.
Feature AD brain 3xTg-AD mice in vivo 3xTg-AD ex vivo brain slice
Tau phosphorylation Increased at many sites16 Increased in 12-15-month old mice12 
in hippocampus but not cortex13
Increased at Ser202 and 
Ser396/404 by 28 DIV15
High molecular weight 
(HMW) tau/tau aggregation
Tau aggregates in characteristic 
neurofibrillary pathology17
HMW and sarkosyl-insoluble 
tau aggregates by 12 months of 
age13, tau aggregates and NFTs 
at 18 months of age12.
64kDa tau at 21 and 28 DIV13
Aβ Increased Aβ deposition in 
hallmark plaques25,26
Increased Aβ-42 at  
6–12 months of age12,13,31, plaques 
from 6 months of age12
Increased Aβ-42 by 14 DIV13
Synaptic protein loss Loss of PSD-95 and  
synapto-physin27,28
Loss of PSD-95 and synaptophysin 
at 13 months of age32, but not  
12 months of age13
No loss of PSD-95 or 
synaptophysin13
Synaptic tau Tau in AD and control synapses, 
but phosphorylated tau 
species only in AD synapses29
Tau at synapses transiently 
increased at 1-2 month of age, 
then returning to control levels 
until 12 months of age13
Tau at synapses transiently 
increased at 14 DIV, then 
returning to normal levels until 
28 DIV13
Synaptic APP APP not increased in AD 
synapses30
Increased APP in synapses at  
1-2 months of age, but not at 
later ages up to 12 months13
No change in synaptic APP13
Another potential therapeutic approach for AD is to use micro-
tubule-stabilising agents to recover the loss of function, 
which occurs following the detachment of phosphorylated tau 
from the microtubule cytoskeleton23. Neuroprotective effects 
of the peptide NAPVSIPQ have previously been reported in 
12-month-old 3xTg-AD mice. Mice administered NAPVSIPQ 
for 3 months showed reduced phosphorylation of tau at Ser 
202/Thr 205 and Thr 231, but not at Ser 202 alone. Treatment 
of 28 DIV 3xTg-AD slice cultures with 100 nM NAPVSIPQ 
for 24 h significantly reduced tau phosphorylation at the Thr231 
epitope, but did not alter the total amount of tau when com-
pared to control cultures15, thus we find that equivalent treatment 
of 3xTg-AD organotypic brain slice cultures recapitulates 
previous in vivo findings conducted in 3xTg-AD mice24,33,34.
Primary data is available at https://www.ncbi.nlm.nih.gov/pmc/ 
articles/PMC5547074/15.
We also used the slice culture model to identify novel tau-
directed effects of BTA-EG415, a compound that had previously 
shown Aβ-binding effects and synaptic protection35–37. A growing 
body of publications have further demonstrated the tractability 
of the slice culture system, including pharmacological manipu-
lation of Aβ production9 and tau aggregation11, in addition to 
modulation of microglial composition to examine the phagocytic 
action of microglia on Aβ deposits22.
These data suggest that potential therapeutic agents can be 
sensitively examined in organotypic brain slice culture models. 
Since a number of methods can be applied to study slice culture 
tissues, this system should be considered as a replacement for 
in vivo studies with molecular and cellular study parameters and 
when end-points do not include life-span or behavioural 
assessment. Certainly, in academic and industrial laboratories, 
slice cultures should provide an excellent system for medium 
throughput drug screening or range-finding studies.
Dataset 1. Primary data for molecular changes in the slice culture 
model in comparison to findings made using tissue from aged 
3xTg-AD mice
http://dx.doi.org/10.5256/f1000research.14500.d200832
Discussion
Organotypic brain slice cultures can reduce the number of 
animals required for some in vivo studies
Depending on the nature of the experiment, one postnatal day 
8 or 9 pup can provide an n=36 for immunohistochemical 
analysis, and a single well containing three slices can be 
combined to give n=12 for biochemical analysis or compound 
screening. For example, the preparation of slice cultures from 
only six postnatal pups would allow the opportunity to study 12 
time-points in six different animals, a reduction in numbers of 
91% in comparison to the 72 mice that would be required for 
an in vivo aging study. In addition, since multiple time points 
will be assessed in tissues from the same animals, experimental 
within-group variation is substantially reduced.
Take-up of this method within academic laboratories in the 
UK appears to be growing, however it is very difficult to accu-
rately quantify the number of animals that have not been used as 
a result of researchers preparing slice cultures in preference to 
in vivo experimentation. Within our own laboratories, we 
estimate that our in vivo experimentation has reduced by 
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approximately 20% as we train more researchers in the method 
of  brain slice culture preparation. 
An adaptable model for neurodegeneration research
While we have focussed on AD research in this article, 
organotypic brain slice cultures are equally suitable for research 
into a range of other neurodegenerative and neurological con-
ditions, as well as for basic neuroscientific research (reviewed 
by 8). Slice cultures can also be prepared specifically from the 
hippocampus9 or from other tissues such as spinal cord38; the 
latter being used to investigate prion-like properties of mutant 
SOD1 proteins in amyotrophic lateral sclerosis. The technique 
is not limited to mice, rats are commonly used8 and methods 
are emerging to allow long-term culture of human organotypic 
brain slice cultures39. There are no major restrictions on uptake 
of this model since it requires only modest investment in terms 
of equipment provision. Training in tissue dissection and slicing 
may be beneficial, but the technique can readily be learned with 
practice.
Conclusions
Here, we describe a detailed method for the preparation of 
long-term organotypic brain slice cultures from postnatal mice. 
We describe our work previously showing that slice cultures pre-
pared from 3xTg-AD mice recapitulate important molecular and 
cellular features of in vivo disease development and the human 
disease phenotype. We also summarise the versatility of the 
model for drug discovery and the acute screening of compounds. 
Slice cultures show a significant acceleration in the timescale 
in which disease features develop, with relevant pathological 
changes observed at 28 days in vitro as opposed to 12 months 
in vivo in 3x-TgAD mice. We suggest that organotypic brain 
slice cultures can be used to replace several in vivo studies and 
that their widespread uptake could reduce the number of animals 
used in neurodegenerative disease research by 20–50%. This 
could be achieved if slice cultures were used in place of purely 
biochemical and immunohistological studies, and for experiments 
not reliant on behavioural outcomes.
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This well written method article describes the process of making whole brain organotypic slices from
3xTg-AD mice to use for studies of Alzheimer’s related pathology. The main focus of the paper is on how
this method can be used to reduce and refine the use of animals in Alzheimer’s disease (AD) research.
The methods of creating and maintaining the slice cultures are clearly described in detail allowing for
future replication by other groups. Specific protocols for preparing slice material for immunostaining,
immunoblotting and ELISA are also described effectively. The experimental results given from previously
published work, as well as the cited work of others, serve as excellent examples of how this system can
be utilised in AD studies with particular emphasis on the 3Rs. In particular, the authors highlight the ability
to test multiple timepoints or multiple compounds on tissue from the same animal resulting in not only a
reduction in the number of animals required, but also better controls for biological variability. I agree with
the authors’ conclusions that brain slice models of Alzheimer’s disease can partly replace
biochemical/cellular/molecular studies in older animals that have developed pathology.
The authors provide a useful comparison between changes observed in human brain, aged 3xTgAD brain
and brain slice cultures, with the raw data provided. Their observations that slice cultures show an
accelerated phenotype when compared to adult mice is interesting and in agreement with what we have
seen in hippocampal slices cultures from TgCRND8 mice (reference 9 in this paper). Future work seeking
to elucidate why this is the case could be very informative.
Whilst the methods in this paper have been previously described elsewhere, the detailed description of
culture preparation, experimental design and methods for analysis in the context of AD are a useful and
timely addition to the literature. The tips relating to assessment of culture health (a white slice becoming
translucent) and issues to look out for that may harm the health of the slices (excess medium on the
membrane insert) are completely aligned with our own experience and very useful for someone seeking
to perform slice culture experiments for the first time. I have no reservations in approving this
manuscript.
Minor comments:
Whilst actin is a valid control protein in western blots, it could be argued that beta-III tubulin (or
alternative neuronal markers) may be a more informative control when normalising synaptic protein
levels. This controls for any difference in neuronal number between samples which may alter
synaptic protein levels in the absence of a synaptic specific change. This would be more important
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 synaptic protein levels in the absence of a synaptic specific change. This would be more important
in cases where synaptic protein levels are down, but there is also evidence for neuronal loss.
 
It would be interesting to see whether the 3xTg-AD brain slices lose synaptic proteins if maintained
for longer than 28 days in vitro. It may be that this phenotype appears after the observed changes
in tau and Aβ in this culture system.
 
It should be stated whether the 3xTg-AD mice used in this study are homozygous or heterozygous
(I am presuming homozygous but this is not explicitly stated). It appears that the wild-type mice
used as controls for the 3xTg-AD are background-matched, but not littermates. This is standard
practice for many homozygous mouse lines but care should be taken to ensure backcrossing of the
two lines to prevent genetic drift between colonies that have remained separated for a long time.
Ideally, littermates would be used, but I understand that the homozygosity of this mouse model
would complicate this and result in a greater number of animals being required to generate all
genotypes. If separate colonies for transgenic and wild type pups are necessary, litters should
ideally be synchronised to control for minor differences in culture preparation/ harvesting on
different days.
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